GlassScriptPhysician profile
Joseph A Cu
NPI 1912086364
$23,526.67
in general payments reported to CMS, 2019-2025
45 companies · $3,344 in 2025
The $3,344 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,632 · 2020: $2,565 · 2021: $3,794 · 2022: $3,264 · 2023: $3,581 · 2024: $3,348 · 2025: $3,344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,067.66 |
| Education | $205.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,974.01 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Novo Nordisk INC | $1,633.17 | 2019-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $1,588.05 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $1,374.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $1,268.70 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,140.39 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $1,038.51 | 2021-2025 | |
| Amarin Pharma, INC. | $994.76 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $976.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $941.95 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $934.16 | 2020-2025 | |
| Esperion Therapeutics, INC. | $852.26 | 2020-2025 | Nexletol, Nexlizet |
| Ibsa Pharma INC. | $833.86 | 2021-2024 | Tirosint, Tirosint, Licart |
| Arbor Pharmaceuticals, INC. | $821.57 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $748.83 | 2021-2024 | Nuzyra |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Cu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.